The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers: Implications for Models of Cognitive Deficits in Schizophrenia
Abstract
BACKGROUND: In patients with schizophrenia, deficient generation of mismatch negativity (MMN)-an event-related potential (ERP) indexing auditory sensory ("echoic") memory-and a selective increase of "context dependent" ("BX") errors in the "A-X" version of the Continuous Performance Test (AX-CPT) indicate an impaired ability to form and use transient memory traces. Animal and human studies implicate deficient N-methyl-D-aspartate receptor (NMDAR) functioning in such abnormalities. In this study, effects of the NMDAR antagonists ketamine on MMN generation and AX-CPT performance were investigated in healthy volunteers to test the hypothesis that NMDARs are critically involved in human MMN generation, and to assess the nature of ketamine-induced deficits in AX-CPT performance. METHODS: In a single-blind placebo-controlled study, 20 healthy volunteers underwent an infusion with subanesthetic doses of ketamine. The MMN-to-pitch and MMN-to-duration deviants were obtained while subjects performed an AX-CPT. RESULTS: Ketamine significantly decreased the peak amplitudes of the MMN-to-pitch and MMN-to-duration deviants by 27% and 21%, respectively. It induced performance deficits in the AX-CPT characterized by decreased hit rates and specific increases of errors (BX errors), reflecting a failure to form and use transient memory traces of task relevant information. CONCLUSIONS: The NMDARs are critically involved in human MMN generation. Deficient MMN in schizophrenia thus suggests deficits in NMDAR-related neurotransmission. N-methyl-D-aspartate receptor dysfunction may also contribute to the impairment of patients with schizophrenia in forming and using transient memory traces in more complex tasks, such as the AX-CPT. Thus, NMDAR-related dysfunction may underlie deficits in transient memory at different levels of information processing in schizophrenia. Arch Gen Psychiatry. 2000;57:1139-1147.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Self-citation(1987) · PubMed · Cited by 2,657
Risto, N. (2018) · Routledge eBooks · doi:10.4324/9780429487354 · Cited by 2,024
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Sensorimotor Gating and Schizophrenia: Human and Animal Model Studies
Braff, D. L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810140081011 · Cited by 1,309
Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075
Gating and Habituation of the Startle Reflex in Schizophrenic Patients
Braff, D. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820030038005 · Cited by 1,027
Cited by
A theory of cortical responses.
Friston, K. (2005) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2005.1622 · Cited by 4,578
The mismatch negativity: a review of underlying mechanisms
Garrido, M. I., Kilner, J. M., Stephan, K. E., & Friston, K. J. (2009) · Clinical Neurophysiology · doi:10.1016/j.clinph.2008.11.029 · Cited by 1,441
“…reductions of MMN amplitude under the NMDA antagonist ketamine (Ehrlichman et al., 2008; Heekeren et al., 2008; Javitt et al., 1996; Kreitschmann-Andermahr et al., 2001; Umbricht et al., 2000, 2002), with only a single study failing to find a significant effect of ketamine (Oranje et al., 2002).”
BackgroundDysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
Stephan, K. E., Friston, K. J., & Frith, C. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn176 · Cited by 1,134
“For example, the NMDA antagonist ketamine reduces the MMN in healthy volunteers, rendering it very similar to that of patients.(54,55) Furthermore, invasive recording studies in monkeys with local infusion of ketamine have demonstrated the dependence of the MMN on NMDARmediated synaptic plasticity;(56) in humans, this…”
ResultMoghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Self-citationLisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010
“In laboratory experiments, a subanesthetic dose of ketamine given to normal volunteers induces the symptoms of schizophrenia more effectively than any other known drug [29–32].”
BackgroundSelf-citationGlutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
The Computational Anatomy of Psychosis
Adams, R. A., Stephan, K. E., Brown, H. R., Frith, C. D., & Friston, K. J. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00047 · Cited by 850
“• Abnormal event-related potentials: such as a larger P50 response to a repeated stimulus, and reduced P300 and mismatch negativity (MMN) responses to violations or oddball stimuli.”
BackgroundMethodInfluentialSynaptic plasticity and dysconnection in schizophrenia
Stephan, K. E., Baldeweg, T., & Friston, K. J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.005 · Cited by 841
“…ERPs of Sensory Learning in Patients can be Mimicked by Pharmacological NMDA Blockage in Healthy Controls Subjects Kreitschmann-Andermahr et al 2001 Umbricht et al 2000 Replicated finding Candidate Genes Identified in Genetic Studies Harrison and Weinberger 2005 (review) Almost all genes are…”
BackgroundMismatch negativity in schizophrenia: a meta-analysis
Umbricht, D., & Krljes, S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.12.002 · Cited by 742
Self-citationMemory‐based or afferent processes in mismatch negativity (MMN): A review of the evidence
Näätänen, R., Jacobsen, T., & Winkler, I. (2005) · Psychophysiology · doi:10.1111/j.1469-8986.2005.00256.x · Cited by 627
Neurophysiological Endophenotypes of Schizophrenia: The Viability of Selected Candidate Measures
Turetsky, B. I., Calkins, M. E., Light, G. A., Olincy, A., Radant, A. D., & Swerdlow, N. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl060 · Cited by 567
Javitt, D. C. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 560
Self-citationMismatch negativity (MMN), the deviance-elicited auditory deflection, explained
May, P. J. C., & Tiitinen, H. (2010) · Psychophysiology · doi:10.1111/j.1469-8986.2009.00856.x · Cited by 549
Glutamate as a therapeutic target in psychiatric disorders
Javitt, D. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001551 · Cited by 524
Self-citationKujala, T., Tervaniemi, M., & Schröger, E. (2007) · Biological Psychology · doi:10.1016/j.biopsycho.2006.06.001 · Cited by 505
When Doors of Perception Close: Bottom-up Models of Disrupted Cognition in Schizophrenia
Javitt, D. C. (2009) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.032408.153502 · Cited by 503
Self-citationOxidative stress in schizophrenia: An integrated approach
Bitanihirwe, B. K. Y., & Woo, T.-U. W. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.008 · Cited by 472
Näätänen, R., Kujala, T., & Winkler, I. (2011) · Psychophysiology · doi:10.1111/j.1469-8986.2010.01114.x · Cited by 456
Convergence of biological and psychological perspectives on cognitive coordination in schizophrenia
Phillips, W. A., & Silverstein, S. M. (2003) · Behavioral and Brain Sciences · doi:10.1017/s0140525x03000025 · Cited by 445
“Both deficits of contextual processing could arise from the same kind of underlying pathology, however, and this view is supported by the finding, noted in section 3, that similar deficits in both mismatch negativity and the CPT are produced in normal volunteers by ketamine (Umbricht et al. 2000).”
BackgroundResultInfluentialNäätänen, R., Kujala, T., Escera, C., Baldeweg, T., Kreegipuu, K., Carlson, S., & Ponton, C. (2012) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.09.020 · Cited by 425
Mismatch Negativity Deficits Are Associated With Poor Functioning in Schizophrenia Patients
Light, G. A., & Braff, D. L. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.127 · Cited by 407
Kantrowitz, J. T., & Javitt, D. C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.04.006 · Cited by 396
Self-citationRedox dysregulation, neurodevelopment, and schizophrenia
Do, K. Q., Cabungcal, J. H., Frank, A., Steullet, P., & Cuenod, M. (2009) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2009.05.001 · Cited by 384
Salisbury, D. F., Kuroki, N., Kasai, K., Shenton, M. E., & McCarley, R. W. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.5.521 · Cited by 379
Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients
Lavoie, S., Murray, M. M., Deppen, P., Knyazeva, M. G., Berk, M., Boulat, O., Bovet, P., Bush, A. I., Conus, P., Copolov, D., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301624 · Cited by 371
Glutamate hypothesis in schizophrenia
Uno, Y., & Coyle, J. T. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12823 · Cited by 367
Auditory dysfunction in schizophrenia: integrating clinical and basic features
Javitt, D. C., & Sweet, R. A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4002 · Cited by 367
Self-citationEarly-stage visual processing and cortical amplification deficits in schizophrenia
Butler, P. D., Zemon, V., Schechter, I., Saperstein, A. M., Hoptman, M. J., Lim, K. O., Revheim, N., Silipo, G., & Javitt, D. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.5.495 · Cited by 362
Self-citationNeurophysiological biomarkers for drug development in schizophrenia
Javitt, D. C., Spencer, K. M., Thaker, G. K., Winterer, G., & Hajós, M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2463 · Cited by 342
Self-citationKetamine-induced changes in rat behaviour: A possible animal model of schizophrenia
Becker, A., Peters, B., Schroeder, H., Mann, T., Huether, G., & Grecksch, G. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00080-0 · Cited by 339
Overview of glutamatergic neurotransmission in the nervous system
Niciu, M. J., Kelmendi, B., & Sanacora, G. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.08.008 · Cited by 329
Sensory Processing in Schizophrenia: Neither Simple nor Intact
Javitt, D. C. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp110 · Cited by 327
Self-citationMismatch negativity potentials and cognitive impairment in schizophrenia
Baldeweg, T., Klugman, A., Gruzelier, J., & Hirsch, S. R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.009 · Cited by 321
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies
Hu, W., MacDonald, M. L., Elswick, D. E., & Sweet, R. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12547 · Cited by 286
Acute and chronic effects of ketamine upon human memory: a review
Morgan, C. J. A., & Curran, H. V. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0572-3 · Cited by 302
Reduced Dendritic Spine Density in Auditory Cortex of Subjects with Schizophrenia
Sweet, R. A., Henteleff, R. A., Zhang, W., Sampson, A. R., & Lewis, D. A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.67 · Cited by 290
The NMDA Receptor and Schizophrenia
Balu, D. T. (2016) · Advances in Pharmacology · doi:10.1016/bs.apha.2016.01.006 · Cited by 285
Mismatch Negativity in Chronic Schizophrenia and First-Episode Schizophrenia
Salisbury, D. F., Shenton, M. E., Griggs, C. B., Bonner-Jackson, A., & McCarley, R. W. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.8.686 · Cited by 284
Prediction of Psychosis by Mismatch Negativity
Bodatsch, M., Ruhrmann, S., Wagner, M., Müller, R., Schultze-Lutter, F., Frommann, I., Brinkmeyer, J., Gaebel, W., Maier, W., Klosterkötter, J., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.057 · Cited by 283
Steullet, P., Cabungcal, J. H., Monin, A., Dwir, D., O'Donnell, P., Cuenod, M., & Do, K. Q. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.021 · Cited by 262
Umbricht, D., Koller, R., Vollenweider, F. X., & Schmid, L. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01242-2 · Cited by 258
Self-citationFrom prediction error to psychosis: Ketamine as a pharmacological model of delusions
Corlett, P. R., Honey, G. D., & Fletcher, P. C. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077716 · Cited by 227
Juvenile Antioxidant Treatment Prevents Adult Deficits in a Developmental Model of Schizophrenia
Cabungcal, J.-H., Counotte, D. S., Lewis, E. M., Tejeda, H. A., Piantadosi, P., Pollock, C., Calhoon, G. G., Sullivan, E. M., Presgraves, E., Kil, J., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.028 · Cited by 204
Farley, B. J., Quirk, M. C., Doherty, J. J., & Christian, E. P. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2793-10.2010 · Cited by 183
“…an important piece of mechanistic information about the MMN derives from the observation that it is diminished in schizophrenia (Michie et al., 2000; Umbricht and Krljes, 2005) and that this disruption can be mimicked by NMDA antagonist treatment in healthy volunteers (Umbricht et al., 2000).”
BackgroundCorlett, P. R., Honey, G. D., Aitken, M. R. F., Dickinson, A., Shanks, D. R., Absalom, A. R., Lee, M., Pomarol-Clotet, E., Murray, G. K., McKenna, P. J., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.611 · Cited by 182
Nonhuman primate model of schizophrenia using a noninvasive EEG method
Gil-da-Costa, R., Stoner, G. R., Fung, R., & Albright, T. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312264110 · Cited by 182
Calcium signalling and psychiatric disease: bipolar disorder and schizophrenia
Berridge, M. J. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1806-z · Cited by 181
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180
“1993), which can be produced in healthy control subjects by low dose ketamine (Umbricht et al. 2000).”
BackgroundModelling trial-by-trial changes in the mismatch negativity
Lieder, F., Daunizeau, J., Garrido, M. I., Friston, K. J., & Stephan, K. E. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002911 · Cited by 168
Translating Glutamate: From Pathophysiology to Treatment
Javitt, D. C., Schoepp, D., Kalivas, P. W., Volkow, N. D., Zarate, C., Merchant, K., Bear, M. F., Umbricht, D., Hajos, M., Potter, W. Z., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002804 · Cited by 168
Self-citationDo, K. Q., Cuenod, M., & Hensch, T. K. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv065 · Cited by 158
Liu, Y., Ouyang, P., Zheng, Y., Mi, L., Zhao, J., Ning, Y., & Guo, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.664535 · Cited by 129
Kulak, A., Steullet, P., Cabungcal, J.-H., Werge, T., Ingason, A., Cuenod, M., & Do, K. Q. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4858 · Cited by 124
Kantrowitz, J. T., Epstein, M. L., Lee, M., Lehrfeld, N., Nolan, K. A., Shope, C., Petkova, E., Silipo, G., & Javitt, D. C. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.02.027 · Cited by 123
Self-citationMismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments
Schmidt, A., Bachmann, R., Kometer, M., Csomor, P. A., Stephan, K. E., Seifritz, E., & Vollenweider, F. X. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.261 · Cited by 121
Modeling ketamine effects on synaptic plasticity during the mismatch negativity
Schmidt, A., Diaconescu, A. O., Kometer, M., Friston, K. J., Stephan, K. E., & Vollenweider, F. X. (2013) · Cerebral Cortex · doi:10.1093/cercor/bhs238 · Cited by 109
Self-citationBaldeweg, T., & Hirsch, S. R. (2015) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2014.03.008 · Cited by 108
Kenemans, J. L., & Kähkönen, S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.157 · Cited by 104
Glutamatergic Modulation of Auditory Information Processing in the Human Brain
Gunduz-Bruce, H., Reinhart, R. M. G., Roach, B. J., Gueorguieva, R., Oliver, S., D'Souza, D. C., Ford, J. M., Krystal, J. H., & Mathalon, D. H. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.031 · Cited by 93
de Bartolomeis, A., Buonaguro, E. F., & Iasevoli, F. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2921-8 · Cited by 89
Lencz, T., Bilder, R. M., Turkel, E., Goldman, R. S., Robinson, D., Kane, J. M., & Lieberman, J. A. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.238 · Cited by 89
Glycine transport inhibitors in the treatment of schizophrenia
Javitt, D. C. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_12 · Cited by 83
Self-citationCarmeli, C., Knyazeva, M. G., Cuénod, M., & Do, K. Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029341 · Cited by 81
Leung, S., Croft, R. J., Baldeweg, T., & Nathan, P. J. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0865-1 · Cited by 81
Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant
Zhu, W., Ding, Z., Zhang, Y., Shi, J., Hashimoto, K., & Lu, L. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0081-2 · Cited by 80
Ranlund, S., Adams, R. A., Díez, Á., Constante, M., Dutt, A., Hall, M., Maestro Carbayo, A., McDonald, C., Petrella, S., Schulze, K., et al. (2016) · Human Brain Mapping · doi:10.1002/hbm.23035 · Cited by 77
“Lastly, reduced MMN amplitudes have been observed in healthy volunteers after NMDA-R blockade, for example by administration of ketamine [Javitt et al., 1996; N€a€at€anen et al., 2012; Schmidt et al., 2012a; Umbricht et al., 2000].”
BackgroundYoshida, T., McCarley, R. W., Nakamura, M., Lee, K., Koo, M.-S., Bouix, S., Salisbury, D. F., Morra, L., Shenton, M. E., & Niznikiewicz, M. A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.004 · Cited by 74
de Bartolomeis, A., Sarappa, C., Buonaguro, E. F., Marmo, F., Eramo, A., Tomasetti, C., & Iasevoli, F. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.06.010 · Cited by 72
Wienberg, M., Glenthoj, B., Jensen, K., & Oranje, B. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109102606 · Cited by 68
A predictive coding account of MMN reduction in schizophrenia
Wacongne, C. (2016) · Biological Psychology · doi:10.1016/j.biopsycho.2015.10.011 · Cited by 68
“Interestingly, the MMN amplitude is reduced by NMDA receptor (NMDA-R) antagonists like PCP and ketamine in normal subjects and in animals (Javitt, Steinschneider, Schroeder, & Arezzo, 1996; Umbricht et al., 2000).”
BackgroundThe profile of cognitive impairments in chronic ketamine users
Ke, X., Ding, Y., Xu, K., He, H., Wang, D., Deng, X., Zhang, X., Zhou, Y., Zhou, C., Liu, Y., et al. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.05.050 · Cited by 67
Effects of chronic ketamine use on frontal and medial temporal cognition
Chan, K. W. S., Lee, T. M. C., Siu, A. M. H., Wong, D. P. L., Kam, C.-M., Tsang, S. K. M., & Chan, C. C. H. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2013.01.014 · Cited by 65
Reduced Auditory Mismatch Negativity Reflects Impaired Deviance Detection in Schizophrenia
Koshiyama, D., Kirihara, K., Tada, M., Nagai, T., Fujioka, M., Usui, K., Araki, T., & Kasai, K. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa006 · Cited by 63
Escudero, I., & Johnstone, M. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0502-8 · Cited by 61
Rosch, R. E., Auksztulewicz, R., Leung, P. D., Friston, K. J., & Baldeweg, T. (2019) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2018.07.003 · Cited by 56
Zick, J. L., Blackman, R. K., Crowe, D. A., Amirikian, B., DeNicola, A. L., Netoff, T. I., & Chafee, M. V. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.010 · Cited by 50
Role of N-Methyl D-aspartate receptors in action-based predictive coding deficits in schizophrenia
Kort, N. S., Ford, J. M., Roach, B. J., Gunduz-Bruce, H., Krystal, J. H., Jaeger, J., Reinhart, R. M. G., & Mathalon, D. H. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.06.019 · Cited by 48
Wang, X., Pinto-Duarte, A., Sejnowski, T. J., & Behrens, M. M. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4907 · Cited by 46
Harms, L., Fulham, W. R., Todd, J., Meehan, C., Schall, U., Hodgson, D. M., & Michie, P. T. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.03.042 · Cited by 40
Davis, M. T., DellaGiogia, N., Maruff, P., Pietrzak, R. H., & Esterlis, I. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01327-5 · Cited by 37
Erickson, M. A., Albrecht, M., Ruffle, A., Fleming, L., Corlett, P., & Gold, J. (2017) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2017.05.002 · Cited by 38
“Glutamate disruption via administration of NMDA antagonists such as ketamine attenuates the MMN in humans (e.g. Umbricht et al., 2000; see also Rosburg and Kreitschmann-Andermahr, 2016 for a meta-analysis) and animals (Tikhonravov et al., 2008).”
BackgroundA predictive coding framework for understanding major depression
Gilbert, J. R., Wusinich, C., & Zarate, C. A. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.787495 · Cited by 38
Uhlhaas, P. J., Millard, I., Muetzelfeldt, L., Curran, H. V., & Morgan, C. J. A. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077739 · Cited by 36
Egerton, A., Fusar-Poli, P., & M. Stone, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799316244 · Cited by 36
Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia
Ballesteros, A., Summerfelt, A., Du, X., Jiang, P., Chiappelli, J., Tagamets, M., O’Donnell, P., Kochunov, P., & Hong, L. E. (2013) · Clinical Neurophysiology · doi:10.1016/j.clinph.2013.05.021 · Cited by 34
André, J. M., Leach, P. T., & Gould, T. J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.12.004 · Cited by 32
Dunn, M. J., & Killcross, S. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.08.028 · Cited by 31
P300 in obsessive–compulsive disorder: Source localization and the effects of treatment
Andreou, C., Leicht, G., Popescu, V., Pogarell, O., Mavrogiorgou, P., Rujescu, D., Giegling, I., Zaudig, M., Juckel, G., Hegerl, U., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.09.003 · Cited by 29
“…with the updating of mental representations according to incoming information (Balconi and Crivelli, 2010; Holmes and Pizzagalli, 2008), i.e. context-processing, which in turn has been shown to be amenable to modulation with glutamatergic agents (Gunduz-Bruce et al., 2012; Umbricht et al., 2000).”
BackgroundKoychev, I., Barkus, E., Ettinger, U., Killcross, S., Roiser, J. P., Wilkinson, L., & Deakin, B. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111414450 · Cited by 24
Electrophysiology of Schizophrenia
Winterer, G., & McCarley, R. W. (2010) · Schizophrenia · doi:10.1002/9781444327298.ch15 · Cited by 23
Hauke, D. J., Charlton, C. E., Schmidt, A., Griffiths, J., Woods, S. W., Ford, J. M., Srihari, V. H., Roth, V., Diaconescu, A. O., & Mathalon, D. H. (2022) · doi:10.1101/2022.12.20.22283712 · Cited by 18
Kim, B., Shin, J., Kim, Y., & Choi, J. H. (2020) · PLOS ONE · doi:10.1371/journal.pone.0230277 · Cited by 11
“Nmethyl-D-aspartate receptors (NMDAR) and the induction of long-term potentiation (LTP) are required for auditory discrimination [44, 58].”
BackgroundGeorge, D. N., Jenkins, T. A., & Killcross, S. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.06.028 · Cited by 8
Suicide prevention and ketamine: insights from computational modeling
Charlton, C. E., Karvelis, P., McIntyre, R. S., & Diaconescu, A. O. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1214018 · Cited by 7
Metadata
- Authors
- Umbricht, D., Schmid, L., Koller, R., Vollenweider, F. X., Hell, D., & Javitt, D. C.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2000-12-01
- Volume
- 57
- Issue
- 12
- Pages
- 1139
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2109848582
- Cited by
- 583
- References
- 82
- FWCI
- 14.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.